Elena Mishchenko

830 total citations · 1 hit paper
12 papers, 461 citations indexed

About

Elena Mishchenko is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Elena Mishchenko has authored 12 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 8 papers in Hematology and 5 papers in Molecular Biology. Recurrent topics in Elena Mishchenko's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Kruppel-like factors research (5 papers). Elena Mishchenko is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Kruppel-like factors research (5 papers). Elena Mishchenko collaborates with scholars based in Israel, United States and United Kingdom. Elena Mishchenko's co-authors include Ayalew Tefferi, Alessandro M. Vannucchi, Éric Jourdan, Claire Harrison, Mark W. Drummond, Tamás Masszi, Mindaugas Jurgutis, Animesh Pardanani, Ruben A. Mesa and Donald Milligan and has published in prestigious journals such as Blood, British Journal of Haematology and Journal of Thrombosis and Haemostasis.

In The Last Decade

Elena Mishchenko

11 papers receiving 457 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis

2015 340 citations Animesh Pardanani, Claire Harrison et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elena Mishchenko Israel	6	384	291	220	159	58	12	461
Emanuil Gheorghita Romania	4	316 0.8×	249 0.9×	182 0.8×	122 0.8×	54 0.9×	4	387
Mindaugas Jurgutis United Kingdom	5	373 1.0×	281 1.0×	203 0.9×	137 0.9×	62 1.1×	7	447
D. W. Kim United States	8	411 1.1×	507 1.7×	67 0.3×	261 1.6×	124 2.1×	9	592
Marc Spentchian France	8	132 0.3×	198 0.7×	134 0.6×	92 0.6×	67 1.2×	12	387
Cristina Bucelli Italy	9	162 0.4×	173 0.6×	81 0.4×	73 0.5×	34 0.6×	33	250
Hyacinthe Johnson‐Ansah France	9	293 0.8×	353 1.2×	31 0.1×	161 1.0×	90 1.6×	18	414
Amity Frede Australia	8	323 0.8×	396 1.4×	58 0.3×	174 1.1×	123 2.1×	13	472
A. Megan Cornelison United States	9	144 0.4×	246 0.8×	92 0.4×	55 0.3×	52 0.9×	16	324
Allison Jeynes-Ellis United States	4	224 0.6×	282 1.0×	47 0.2×	124 0.8×	79 1.4×	5	400
Mahran Shoukier United States	9	71 0.2×	115 0.4×	78 0.4×	21 0.1×	94 1.6×	23	249

Countries citing papers authored by Elena Mishchenko

Since Specialization

Citations

This map shows the geographic impact of Elena Mishchenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elena Mishchenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elena Mishchenko more than expected).

Fields of papers citing papers by Elena Mishchenko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elena Mishchenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elena Mishchenko. The network helps show where Elena Mishchenko may publish in the future.

Co-authorship network of co-authors of Elena Mishchenko

This figure shows the co-authorship network connecting the top 25 collaborators of Elena Mishchenko. A scholar is included among the top collaborators of Elena Mishchenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elena Mishchenko. Elena Mishchenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Деменков, П. С., Elena Mishchenko, Т. М. Хлебодарова, et al.. (2023). Prioritization of potential pharmacological targets for the development of anti-hepatocarcinoma drugs modulating the extrinsic apoptosis pathway: the reconstruction and analysis of associative gene networks help. Vavilov Journal of Genetics and Breeding. 27(7). 784–793. 1 indexed citations

Pardanani, Animesh, Ayalew Tefferi, Tamás Masszi, et al.. (2021). Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis. British Journal of Haematology. 195(2). 244–248. 40 indexed citations

Saliba, Walid, Elena Mishchenko, Shai Cohen, Gad Rennert, & Meir Preis. (2020). Association between myelofibrosis and thromboembolism: A population‐based retrospective cohort study. Journal of Thrombosis and Haemostasis. 18(4). 916–925. 16 indexed citations

Pardanani, Animesh, Ayalew Tefferi, Tamás Masszi, et al.. (2020). Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial. Blood. 136(Supplement 1). 10–12. 2 indexed citations

Ellis, Martin, Noa Lavi, Elena Mishchenko, et al.. (2015). Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice. Leukemia Research. 39(11). 1154–1158. 7 indexed citations

Pardanani, Animesh, Claire Harrison, Jörge E. Cortes, et al.. (2015). Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. JAMA Oncology. 1(5). 643–643. 340 indexed citations breakdown →

Mishchenko, Elena, Dina Attias, & Tamar Tadmor. (2014). Response of cutaneous lesion of mantle cell lymphoma to lenalidomide. International Journal of Hematology. 100(1). 1–2. 1 indexed citations

Ellis, Martin, Noa Lavi, Elena Mishchenko, et al.. (2014). Ruxolitinib Treatment for Myelofibrosis: Efficacy and Tolerability in a Real-World Setting. Blood. 124(21). 1830–1830. 1 indexed citations

Mesa, Ruben A., Jörge E. Cortes, Francisco Cervantes, et al.. (2013). Symptom Burden and Health-Related Quality Of Life (HRQoL) In Patients With Myelofibrosis (MF) Treated With Fedratinib (SAR302503) In a Phase III Study (JAKARTA). Blood. 122(21). 4061–4061. 3 indexed citations

10.

Pardanani, Animesh, Claire Harrison, Jörge E. Cortes, et al.. (2013). Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF). Blood. 122(21). 393–393. 27 indexed citations

11.

Mishchenko, Elena & Ayalew Tefferi. (2010). Treatment options for hydroxyurea‐refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. European Journal Of Haematology. 85(3). 192–199. 18 indexed citations

12.

Mishchenko, Elena, Tamar Tadmor, Elad Schiff, Dina Attias, & Aaron Polliack. (2010). Hypereosinophilia, JAK2V617F, and Budd‐Chiari syndrome: Who is responsible for what?. American Journal of Hematology. 86(2). 223–224. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact